What is the 13F Pro Quality Score for VNRX?

13F Pro ranks VOLITIONRX LTD (VNRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VNRX's current score at https://13fpro.ai/company/VNRX (free sign-up required for the full ranking).

Where does 13F Pro source VNRX data?

All VOLITIONRX LTD fundamentals and ownership data come directly from SEC EDGAR. VOLITIONRX LTD files with the SEC under CIK 93314. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VNRX in?

VOLITIONRX LTD (VNRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VNRX research updated on 13F Pro?

VNRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

VOLITIONRX LTD(VNRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 93314 VNRX stock profile & AI dashboard →

13F Pro Quality Score

26.1/100

Rank #2,633 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why VNRX Scores 26/100

exact factor attribution · 2026-09-11

VNRX's composite is driven by revenue growth, held back by scale and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.8 pts

94th pct

Institutional flow

-1.2 pts

26th pct

Earnings quality

-1.7 pts

33th pct

Shareholder dilution

-2.2 pts

6th pct

Earnings growth

-2.2 pts

5th pct

Capital efficiency

-4.9 pts

1th pct

Profitability

-6.7 pts

6th pct

Free cash flow

-6.8 pts

5th pct

Scale

-6.9 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

VNRX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for VOLITIONRX LTD (VNRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VNRX at 26.1/100 on a 32-signal composite quality model, placing it at rank #2,633 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), VOLITIONRX LTD reports quarterly revenue of $398.7K, net income of $-7.3M, free cash flow of $-5.2M. Top institutional holders of VNRX by reported 13-F value include Lagoda Investment Management, L.P., LUMINUS MANAGEMENT, GEODE CAPITAL MANAGEMENT, based on the most recent SEC filings. VNRX trades on the NYSE exchange and files with the SEC under CIK 93314. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VNRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for VOLITIONRX LTD directly from SEC EDGAR.

Revenue

Q2 2026

$398.7K

Net Income

Q2 2026

$-7.3M

Free Cash Flow

Q2 2026

$-5.2M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+40.0% YoY

$1.7MFY 2025

FY22 $306.4KFY23 $775.3KFY24 $1.2MFY25 $1.7M

Net Income

+13.4% YoY

$-23.4MFY 2025

FY22 $-30.6MFY23 $-35.7MFY24 $-27.0MFY25 $-23.4M

Operating Income

+19.6% YoY

$-21.7MFY 2025

FY22 $-31.8MFY23 $-36.0MFY24 $-27.0MFY25 $-21.7M

EPS (Diluted)

—FY 2025

FY22 —FY23 $-0.50FY24 $-0.31FY25 —

Total Assets

-26.6% YoY

$6.9MFY 2025

FY22 $18.3MFY23 $28.0MFY24 $9.4MFY25 $6.9M

Total Debt

+34.0% YoY

$7.6MFY 2025

FY22 $4.9MFY23 $6.0MFY24 $5.7MFY25 $7.6M

Op. Cash Flow

+24.0% YoY

$-19.7MFY 2025

FY22 $-15.3MFY23 $-18.1MFY24 $-25.9MFY25 $-19.7M

Free Cash Flow

+24.4% YoY

$-19.8MFY 2025

FY22 $-16.8MFY23 $-19.1MFY24 $-26.2MFY25 $-19.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.7M +40.0%	$1.2M +59.1%	$775.3K +153.0%	$306.4K +240.3%	$90.0K +570.3%	$13.4K
Net Income	$-23.4M +13.4%	$-27.0M +24.4%	$-35.7M -16.6%	$-30.6M -122.3%	$137.0M +24.3%	$110.2M
Operating Income	$-21.7M +19.6%	$-27.0M +24.9%	$-36.0M -13.2%	$-31.8M -12.2%	$-28.3M -33.3%	$-21.2M
EPS (Diluted)	—	$-0.31 +38.0%	$-0.50	—	—	—
Total Assets	$6.9M -26.6%	$9.4M -66.4%	$28.0M +52.8%	$18.3M -33.4%	$27.5M +5.1%	$26.2M
Total Debt	$7.6M +34.0%	$5.7M -6.1%	$6.0M +22.9%	$4.9M +27.1%	$3.9M -9.9%	$4.3M
Operating Cash Flow	$-19.7M +24.0%	$-25.9M -43.4%	$-18.1M -18.2%	$-15.3M +26.7%	$-20.9M -26.7%	$-16.5M
Free Cash Flow	$-19.8M +24.4%	$-26.2M -36.7%	$-19.1M -13.6%	$-16.8M +22.8%	$-21.8M -18.6%	$-18.4M

Get alerted when VNRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for VOLITIONRX LTD including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VNRX

Lagoda Investment Management, L.P.
$2.0M1,455,950 sh
LUMINUS MANAGEMENT LLC
$211.8K156,897 sh
GEODE CAPITAL MANAGEMENT, LLC
$75.0K55,537 sh
VANGUARD CAPITAL MANAGEMENT LLC
$68.4K50,684 sh
Wealthspire Advisors, LLC
$60.8K45,000 sh
STATE STREET CORP
$45.9K33,995 sh
XTX Topco Ltd
$34.3K25,381 sh
VANGUARD FIDUCIARY TRUST CO
$33.9K25,133 sh
BlackRock, Inc.
$30.1K22,308 sh
NORTHERN TRUST CORP
$17.5K12,978 sh

Fund	Value	Shares
Lagoda Investment Management, L.P.	$2.0M	1,455,950
LUMINUS MANAGEMENT LLC	$211.8K	156,897
GEODE CAPITAL MANAGEMENT, LLC	$75.0K	55,537
VANGUARD CAPITAL MANAGEMENT LLC	$68.4K	50,684
Wealthspire Advisors, LLC	$60.8K	45,000
STATE STREET CORP	$45.9K	33,995
XTX Topco Ltd	$34.3K	25,381
VANGUARD FIDUCIARY TRUST CO	$33.9K	25,133
BlackRock, Inc.	$30.1K	22,308
NORTHERN TRUST CORP	$17.5K	12,978

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VNRX on your watchlist

Track score changes the day VOLITIONRX LTD files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VNRX a good stock to buy?

13F Pro's AI-powered analysis of VOLITIONRX LTD (VNRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VNRX are available on the VNRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VNRX is classified as a small company.

Which hedge funds own VNRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VNRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of VOLITIONRX LTD's investment landscape.